•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Buy, Sell, or Hold? Tuesday’s Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
Sarepta Therapeutics Q3 Earnings Call Highlights
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT